• Nigericin Sodium Salt: Protocols for Ion Transport Studies

  2026-05-13

  Nigericin sodium salt is a potassium ionophore that enables precise modulation of ion transport across biological membranes, with applications in cytoplasmic pH regulation, platelet aggregation studies, and selective Pb2+ ion transport. It is not suitable for diagnostic or medical use and should be handled under stringent laboratory protocols for scientific research only.

• Nystatin (Fungicidin): Reliable Antifungal Solutions for Res

  2026-05-13

  This article explores laboratory scenarios where Nystatin (Fungicidin) (SKU B1993) delivers reproducible, data-driven solutions to common assay challenges. It highlights validated use cases and protocol guidance for biomedical researchers, emphasizing the product’s compatibility, rigor, and evidence-backed performance.

• hiPSC-Derived Intestinal Organoids Enable Human Pharmacokine

  2026-05-12

  This study establishes a streamlined protocol for generating human induced pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) with high proliferative and differentiation capacity. The resulting organoids provide a more physiologically relevant in vitro model for pharmacokinetic and drug metabolism research, overcoming limitations of animal models and conventional cell lines.

• Lipid Nanoparticle Structure and Administration Shape mRNA D

  2026-05-12

  Chaudhary et al. provide key insights into how the structure of lipid nanoparticles (LNPs) and the route of administration influence the potency, immunogenicity, and maternal-fetal safety of mRNA therapies during pregnancy. Their work delivers mechanistic guidance for designing LNP-mRNA systems, addressing a critical gap in safe RNA-based interventions for pregnancy-related disorders.

• O-GlcNAcylation Regulates Ferroptosis and Trophoblast Syncyt

  2026-05-11

  This study uncovers how O-GlcNAc modification of HUWE1 orchestrates the ubiquitination of transferrin receptor 1 (TfR1), regulating iron uptake, ferroptosis, and syncytialization in placental trophoblasts during preeclampsia. The findings establish O-GlcNAcylation as a pivotal modulator of placental pathology and suggest new mechanistic targets for mitigating adverse pregnancy outcomes.

• EPZ-6438 (SKU A8221): Precision EZH2 Inhibition in Epigeneti

  2026-05-11

  This article explores real-world laboratory scenarios where EPZ-6438 (SKU A8221) addresses challenges in cell viability, proliferation, and cytotoxicity assays. By integrating evidence-based Q&A, it demonstrates how this highly selective EZH2 inhibitor supports reproducible, data-driven workflows for biomedical researchers.

• Deferasirox: Oral Iron Chelator for Targeted Iron Metabolism

  2026-05-10

  Deferasirox is redefining research on iron overload and cancer by enabling precise control of cellular iron pools and metabolic stress responses. This article delivers a protocol-centric guide to experimental workflows, troubleshooting, and advanced applications—bridging recent insights into nutrient sensing and ferroptosis resistance.

• Cholesterol Impairs Lipid Nanoparticle Trafficking in Cells

  2026-05-09

  This study reveals that elevated cholesterol levels in lipid nanoparticles (LNPs) hinder their intracellular trafficking and cargo delivery by promoting aggregation in early endosomes. The research leverages a highly sensitive streptavidin–biotin-DNA tracking platform, offering mechanistic insight for optimizing LNP formulations in nucleic acid delivery applications.

• Meropenem Trihydrate in Resistance Phenotyping Workflows

  2026-05-08

  Meropenem trihydrate unlocks advanced, reproducible workflows for antibiotic resistance studies and robust infection modeling. Explore stepwise protocols, troubleshooting strategies, and the transformative impact of metabolomics-based resistance detection, all leveraging APExBIO’s rigorously validated carbapenem antibiotic.

• LY294002: Translational Leverage in PI3K Pathway and Beyond

  2026-05-08

  This article provides translational researchers with a mechanistic, evidence-driven framework for deploying LY294002—a potent, reversible class I PI3K inhibitor—in the interrogation of PI3K/Akt/mTOR signaling, autophagy, and apoptosis. Drawing from recent neuroinflammation and oncology studies, we discuss protocol optimization, emerging cross-domain applications, and next-generation experimental strategies. The narrative integrates primary literature, product intelligence, and competitive context, demonstrating how APExBIO’s LY294002 advances research beyond conventional use cases.

• A 83-01 (ALK-5 Inhibitor): Precision Control in Human Organo

  2026-05-07

  Explore how A 83-01, a selective ALK-5 inhibitor, enables refined modulation of TGF-β signaling for balancing self-renewal and differentiation in advanced human organoid research. Discover new assay strategies grounded in recent breakthroughs.

• Meropenem: A Carbapenem Benchmark for Resistance Modeling &

  2026-05-07

  Explore Meropenem, an ultra-broad-spectrum β-lactam antibiotic carbapenem, as a precision tool for dissecting resistance in Gram-negative and Gram-positive bacteria. This article uniquely focuses on translational assay design, protocol optimization, and practical insights for research models.

• Predicting Compound Mechanism Across Cell Lines Using ML Cla

  2026-05-06

  Warchal et al. critically evaluated machine learning classifiers for predicting compound mechanism of action (MoA) using high-content image data across genetically distinct cancer cell lines. Their findings reveal the strengths and limitations of ensemble-based and deep learning approaches, with important implications for phenotypic drug screening and translational cancer research.

• JC-1 Fluorescent Probe: Optimizing Mitochondrial Potential A

  2026-05-06

  JC-1 enables high-sensitivity, ratiometric assessment of mitochondrial membrane potential, powering advanced apoptosis and bioenergetics research. This guide delivers actionable protocols, experimental troubleshooting, and translational insights derived from cutting-edge cancer studies, ensuring robust data and reproducibility for cell-based assays.

• Comparative Antibacterial Activity of Cefoperazone and New β

  2026-05-05

  This article analyzes Cullmann et al.'s landmark comparison of N-formimidoyl thienamycin (MK0787) with recently developed β-lactam antibiotics—including cefoperazone—against a diverse panel of resistant clinical isolates. The findings inform selection criteria for in vitro antimicrobial activity assays and resistance studies, highlighting both compound-specific advantages and methodological considerations.

13480 records 1/899 page Next 12345 下5页 Last page